Identification of multicohort-based predictive signature for NMIBC recurrence reveals SDCBP as a novel oncogene in bladder cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new 8-gene signature can predict non-muscle invasive bladder cancer (NMIBC) recurrence. Targeting SDCBP may also help delay bladder cancer relapse.
Area Of Science
- Oncology
- Genomics
- Biomarkers
Background
- Non-muscle invasive bladder cancer (NMIBC) has a high recurrence rate despite treatment.
- Current clinical factors are insufficient for accurate recurrence risk assessment.
- Novel predictive tools are needed for NMIBC management.
Purpose Of The Study
- To develop and validate a gene signature for predicting NMIBC recurrence.
- To construct a clinical nomogram integrating gene signature and clinicopathological factors.
- To investigate the biological role of SDCBP in bladder cancer progression.
Main Methods
- Analysis of NMIBC microarray data from public databases (ArrayExpress, GEO).
- Development of a predictive gene signature using LASSO regression.
- Construction of a clinical nomogram incorporating gene signature and clinicopathological factors.
- Experimental validation of SDCBP functions in vitro and in vivo.
Main Results
- An 8-gene signature was developed and validated for predicting NMIBC recurrence.
- Elevated ACTN4 and SDCBP levels were observed in recurrent NMIBC tissues.
- A nomogram integrating SDCBP and clinical factors demonstrated superior predictive accuracy.
- SDCBP promotes bladder cancer progression through angiogenesis, EMT, and metastasis.
- Silencing SDCBP inhibited cell growth and key metabolic pathways.
Conclusions
- The 8-gene signature is a promising tool for predicting NMIBC recurrence.
- Targeting SDCBP presents a potential therapeutic strategy to delay bladder cancer relapse.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
